Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI7510 RSV vaccine in older adults
NCT02115815Phase 1Completed
- Sponsor
- MedImmune
- Start
- Apr 2014
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEDI7510 in respiratory syncytial virus infection (RSV) (7 arms), sponsored by MedImmune. Primary endpoints: Number of Participants With Solicited Symptoms at 7 days, Treatment-Emergent Adverse Events at 28 days and 1 more. Started Apr 2014; status: completed.
02
Drugs
MEDI7510
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02115815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115815.